MYC gene amplification drives protein overexpression and its clinical prognostic value in prostate cancer: a study of 152 Chinese cases
American Journal of Clinical Pathology · 04.06.2026 · 165 (6)
DOI: 10.1093/ajcp/aqag059 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 17.06.2026. Verfasst von Mei Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan Province, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Gene Amplification, Adenocarcinoma, Biomarkers, Tumor. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Horizontal Project of West China Fourth Hospital, Sichuan University.
Abstract (Originalsprache)
Objectives
To investigate the expression patterns of ERG, PTEN, and c-Myc proteins in prostate adenocarcinoma; analyze the status of the MYC gene; and evaluate their correlations with clinicopathologic parameters and patient prognosis.
Methods
In this retrospective study, 152 prostate adenocarcinoma cases were analyzed. Immunohistochemistry was performed for ERG, PTEN, and c-Myc protein expression. Fluorescence in situ hybridization was used to assess ERG rearrangement, MYC gene breakage, and amplification. Statistical analyses were conducted to evaluate associations between molecular markers and clinicopathologic variables, as well as their impact on survival outcomes.
Results
The positive expression rates for ERG, PTEN, and c-Myc high expression (immunoreactive score ≥5) were 9.9%, 86.8%, and 50%, respectively. The detection rate of MYC gene amplification was 27.6%. Both c-Myc high expression and MYC gene amplification were significantly associated with the high-grade group (defined as Grade Group ≥3 and/or with cribriform pattern), lymphovascular invasion, advanced T stage, metastasis, and poor prognosis, with gene amplification demonstrating higher prognostic specificity. ERG protein expression was significantly correlated with PTEN positivity, whereas no significant association was found between MYC gene amplification and ERG protein expression; only a nonsignificant mutually exclusive trend was observed. Conclusions c-Myc activation, particularly MYC gene amplification, is a key driver and specific biomarker for an aggressive phenotype and poor prognosis in prostate adenocarcinoma. Combined detection of ERG, PTEN, and c-Myc status contributes to refining risk stratification systems. The lack of significant association between MYC amplification and ERG expression suggests they may represent distinct oncogenic pathways, warranting further validation in large prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan Province, China.
- Department of Pathology, Mianyang Central Hospital, Mianyang, Sichuan Province, China.
Förderung
- Horizontal Project of West China Fourth Hospital, Sichuan University
Zitieren
APA
Tang, M., Xie, C., Huang, R., Lei, C., Yu, X., & Zhou, P. (2026). MYC gene amplification drives protein overexpression and its clinical prognostic value in prostate cancer: a study of 152 Chinese cases. American Journal of Clinical Pathology, 165(6). https://doi.org/10.1093/ajcp/aqag059
Vancouver
Tang M, Xie C, Huang R, Lei C, Yu X, Zhou P. MYC gene amplification drives protein overexpression and its clinical prognostic value in prostate cancer: a study of 152 Chinese cases. American Journal of Clinical Pathology. 2026;165(6). doi:10.1093/ajcp/aqag059
BibTeX
@article{Tang2026,
author = {Tang, Mei and Xie, Chunyan and Huang, Rongfei and Lei, Chuanfen and Yu, Xianjing and Zhou, Ping},
title = {MYC gene amplification drives protein overexpression and its clinical prognostic value in prostate cancer: a study of 152 Chinese cases},
journal = {American Journal of Clinical Pathology},
year = {2026},
volume = {165},
number = {6},
doi = {10.1093/ajcp/aqag059}
}
EUVIMED